
US-based biotechnology firm Momenta Pharmaceuticals has announced that its biosimilar version of Abbvie’s autoimmune drug Humira (adalimumab) – currently the …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

